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Diabetic retinopathy is a leading cause of acquired
blindness. Visual function disorders have been ob-
served in diabetic patients with very early retinopa-
thy or even before the onset of retinopathy. The aim
of the present work was to analyze the visual pathway
in an early stage of experimental diabetes. Diabetes
was induced in Wistar rats by an i.p. injection of
streptozotocin. A deficit in anterograde transport
from the retina to the superior colliculus was ob-
served 6 weeks after streptozotocin injection. At this
time point, morphologic studies did not reveal retinal
ganglion cell loss or substantial alterations in the su-
perior colliculus. The optic nerve was morphometri-
cally evaluated at intraorbital (unmyelinated and my-
elinated) and intracranial sections. In animals that
had been diabetic for 6 weeks, a large increase in
astrocyte reactivity occurred in the distal (but not the
intraorbital) portion, which coincided with signifi-
cant axon loss. Moreover, profound myelin altera-
tions and altered morphologic features of oligoden-
drocyte lineage were observed at the distal (but not
the proximal) optic nerve portion. The present re-
sults suggest that axoglial alterations at the distal por-
tion of the optic nerve could be the first structural
change in the diabetic visual pathway. (Am J Pathol
2012, 180:303–313; DOI: 10.1016/j.ajpath.2011.09.018)Diabetic retinopathy (DR) is a leading cause of acquired
blindness. DR is rarely detected in the first few years of
diabetes, but its incidence increases to 50% by 10 years
and to 90% by 25 years of diabetes. Vision loss mainly
occurs due to chronic hyperglycemia, vascular damage
and leakage, edema formation, capillary basement mem-
brane thickening, neovascularization, hemorrhage, and
ischemia.1 Although DR has long been recognized as a
vascular disease, it is becoming increasingly clear that
retinal cells are also affected by diabetes, resulting in
dysfunction and degeneration of neuronal cells (reviewed
by Kern and Barber2). However, the progression rate of
retinal cell degeneration is still controversial. Barber et al3
showed decreases in retinal ganglion cell (RGC) number
and in inner plexiform layer thickness, which occur after
7.5 months of streptozotocin (STZ)-induced diabetes in
rats, whereas Kusari et al4 reported a loss of RGCs at 4
weeks of STZ injection. Moreover, Seigel et al5 demon-
strated an increase in the number of apoptotic RGCs
after 3 months of diabetes.
Visual function disorders have been demonstrated in
diabetic patients with very early retinopathy or even be-
fore the onset of retinopathy. Psychophysical methods
and electrophysiologic measurements have yielded ab-
normalities in visual pathway function,6 such as reduced
contrast sensitivity,7–10 reduced pattern electroretino-
gram amplitude,11,12 and conduction delays of visual
evoked potentials.13–16 In that sense, it was demon-
strated that the impaired visual evoked potentials are due
to early involvement of nervous conduction in the optic
nerve (ON).15 Moreover, in an experimental model of
diabetes in rats, a significant reduction in mean myelin-
ated fiber size in the diabetic ON has been reported.17,18
Thus, it seems likely that diabetic neurosensory disorders
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changes but also to those in the ON or higher visual
pathway.19 Because most of the previously published
literature focuses on the effect of diabetes on the retina,
and does not correlate this effect with ON and visual
pathway structure, we considered it worthwhile to ana-
lyze the morphologic appearance of the visual pathway in
an early stage of experimental diabetes.
Materials and Methods
Animals
All the animal procedures were conducted in accordance
with the Association for Research in Vision and Ophthal-
mology Statement for the Use of Animals in Ophthalmic
and Vision Research. Male Wistar rats (mean  SD
weight, 300  50 g) were housed in a standard animal
room with food and water ad libitum under controlled
conditions of humidity and temperature (mean  SD,
21°C  2°C) and under a 12-hour light/12-hour dark
lighting schedule (lights on at 8:00 AM). For diabetes
induction, a single dose of STZ (Sigma-Aldrich, St. Louis,
MO), 60 mg/kg (in 0.1 mol/L citrate buffer, pH 4.5), was
i.p. injected. Control rats received an equal volume of
citrate buffer. The animals were examined 72 hours after
injection using a glucose meter (Contour TS, Bayer, Bue-
nos Aires, Argentina), and those with blood glucose lev-
els greater than 350 mg/dL were considered diabetic.
Body weight and plasma glucose level were determined
weekly.
Tissue Processing
Anesthetized rats were intracardially perfused with saline
solution, followed by a fixative solution containing 4%
formaldehyde in 0.1 mol/L PBS (pH 7.4). Then, the eye-
balls with the intraorbital ON portion and the brain with
the intracranial ON portion were carefully removed and
immersed for 24 hours in the same fixative. ONs behind
the eye (the intraorbital portion containing the ON head)
and 2 mm before the optic chiasm (intracranial portion)
were dissected out and used for semithin sectioning or
immunostaining. After several washings, some tissue
blocks were postfixed in 2% aqueous osmium tetroxide in
sodium phosphate buffer for 1 hour. Dehydration was
accomplished by gradual ethanol series, and tissue sam-
ples were embedded in epoxy resin. Semithin sections (1
m) were obtained using an ultramicrotome, stained with
toluidine blue, and used for morphometric analysis. Light
microscopic images were digitally captured using a
Nikon Eclipse E400 microscope via a Nikon Coolpix s10
camera (Nikon, Tokyo, Japan). In some cases, the ONs
were dehydrated and embedded in paraffin. Transverse
sections (7 m) were obtained and used for immuno-
staining. Eyes were embedded in paraffin and were sec-
tioned (5 m) along the vertical meridian through the ON
head. Sections were stained with H&E.
The brains were coronally sectioned (behind the optic
chiasm), and the anterior portion was included in paraffin
as previously described.20 Horizontal sections (10 m)were obtained at the level of the optic chiasm (containing
the ON and the optic tract portions). The posterior portion
of the brain was immersed in a graded series of sucrose
solutions (10%, 20%, and 30%), and coronal sections (40
m) were obtained using a Leica CM1850 freezing mi-
crotome (Leica Microsystems Inc., Buffalo Grove, IL).
Cholera Toxin -Subunit Injection
Rats (five animals per group) were anesthetized, and a
drop of proparacaine (0.5%) was topically administered
for local anesthesia. Four microliters of a solution of 0.2%
cholera toxin -subunit (CTB) conjugated to Alexa 488
dye (Molecular Probes Inc., Eugene, OR) in 0.1 mol/L
PBS (pH 7.4) was injected into the vitreous using a 30-
gauge Hamilton syringe (Hamilton, Reno, NV). The injec-
tions were applied 1 mm from the limbus, and the needle
was left in the eye for 1 minute to prevent volume loss.
Three days after injection, the rats were anesthetized and
intracardially perfused as described previously herein.
Their brains were carefully removed, postfixed overnight
at 4°C, and immersed in a graded series of sucrose
solutions; coronal sections (40 m) were obtained using
a freezing microtome. Nuclei were stained with the fluo-
rescent dye DAPI, mounted with antifade medium, and
viewed with a fluorescence microscope as described.
TUNEL Assay
For DNA fragmentation of cells undergoing apoptosis,
the ApopTag fluorescein in situ apoptosis detection kit
[S7110, Chemicon (Millipore), Temecula, CA] was used
according to the manufacturer’s instructions. For each
retinal section, the number of TUNEL cells along the
entire retina was calculated. For each eye, results ob-
tained from four separate sections were averaged, and
the mean of five eyes was recorded as the representative
value for each group. For each superior colliculus (SC),
three sections per animal were evaluated (rostral, medial,
and caudal portions), and the number of TUNEL cells
was counted in the stratum zonale and the stratum gri-
seum superficiale layers. The mean of five SC values was
recorded as the representative value for each group.
Immunostaining Protocol
The following antibodies were used: a mouse monoclonal
anti–glial fibrillary acidic protein (GFAP) antibody conju-
gated to Cy3 (1:800; Sigma-Aldrich), a rabbit polyclonal
anti–myelin basic protein (MBP) antibody, a mouse poly-
clonal IgM O1 antibody, a goat polyclonal anti–platelet-
derived growth factor receptor- (PDGFR-) antibody (1:
100; Neuromics, Edina, MN), a mouse monoclonal anti-
CD11b antibody (Abd Serotec, Raleigh, NC), a mouse
monoclonal anti-ED1 (CD68) antibody (Abcam Inc.,
Cambridge, MA), a goat anti-rabbit secondary antibody
conjugated to Cy2 (1:100; Jackson ImmunoResearch
Laboratories Inc., West Grove, PA), a donkey anti-mouse
IgM secondary antibody conjugated to Cy3 (1:200; Jack-
son ImmunoResearch Laboratories Inc.), and a donkey
anti-goat secondary antibody conjugated to DyLight 488
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The biotinylated lectin Griffonia simplicifolia I (Isolectin B4,
1:200; Vector Laboratories, Burlingame, CA) was used
for microglia staining. The anti-MBP and O1 antibodies
were a gift from Dr. A.T. Campagnoni (Mental Retardation
Research Center, University of California, Los Angeles,
CA). Some sections were immersed in 0.1% Triton X-100
(Roche Diagnostics GmbH, Mannheim, Germany) in 0.1
mol/L PBS for 10 minutes. Antigen retrieval was per-
formed in paraffin sections by heating (90°C) slices for 30
minutes in citrate buffer (pH 6.3). Sections were preincu-
bated with 5% normal horse serum for 1 hour and then
were incubated overnight at 4°C with primary antibodies.
For double labeling, the antibodies were used at the
concentrations listed previously herein. After several
washings, secondary antibodies were added, and sec-
tions were incubated for 2 hours at room temperature.
Regularly, some sections were treated without the pri-
mary antibodies to confirm specificity. After immunostain-
ing, nuclei were stained with DAPI, mounted using anti-
fade medium (Vectashield; Vector Laboratories), and
viewed using a fluorescence microscope (BX50; Olym-
pus, Tokyo, Japan) connected to a video camera (3CCD;
Sony, Tokyo, Japan) attached to a computer running
image analysis software (Image-Pro Plus; Media Cyber-
netics Inc., Bethesda, MD). For microglial cell analysis,
sections were incubated for 48 hours at 4°C with lectin,
and after several washings, the LSAB2 System-HRP
(DakoCytomation, Carpinteria, CA) was used accord-
ing to the manufacturer’s instructions.
Electron Microscopy
After anesthesia and thoracotomy, the animals were per-
fused through the left ventricle with a fixative solution
containing 2% glutaraldehyde and 4% formaldehyde in
0.1 mol/L PBS (pH 7.4). Semithin sections were obtained
as described previously hererin, and ultrathin sections
were stained with uranyl acetate and lead citrate. Finally,
sections were viewed and photographed using a Zeiss
EM 10C transmission electron microscope (Carl Zeiss
Microscopy, Peabody, MA).
Morphometric Analysis
All the images obtained were assembled and processed
using Adobe Photoshop SC (Adobe Systems, San Jose,
CA) to adjust the brightness and contrast. No other ad-
justments were made. For all the morphometric image
processing and analysis, digitalized captured TIFF im-
ages were transferred to ImageJ software version 1.42q
(NIH, Bethesda, MD). All the nomenclature used herein
follows that of Paxinos and Watson.21
ON Analysis
ON total area was calculated from light microphoto-
graphs of transverse semithin sections obtained at a final
magnification of 20. The nerve was divided into four
quadrants, and the number and area of axons were cal-
culated in each section (in areas randomly chosen ineach quadrant) from micrographs obtained at a magnifi-
cation of 100. Images were converted to 8-bit gray-
scale, and a manual threshold value, first determined by
visual examination, was constantly applied. Finally, im-
ages were converted to a binary form. Myelinated fiber
sizes were digitally delineated by the outer margin of their
myelin sheaths, and axon areas were measured. For
each ON, results obtained from four separate sections
were averaged, and the mean axon number and area of
five nerves were recorded as the representative values
for each group. Histograms of nerve fiber size distribution
were obtained using Origin software (OriginLab Corp.,
Northampton, MA). Electron microscopic photographs
were obtained at a final magnification of 3000. Fiber
number and axon area were calculated from approxi-
mately 10 photographs per nerve. The g-ratios were cal-
culated from no fewer than 500 myelinated axons per
nerve. Data from four nerves were averaged and re-
corded as the representative value for each group.
Ganglion Cell Layer Cell Density
Microscopic images with a final magnification of 40
were obtained as previously described.22 Total retinal,
inner plexiform layer, inner nuclear layer, and outer nu-
clear layer thicknesses were measured for each eye, and
the number of cells in the ganglion cell layer (GCL) was
counted along 200 m for each section. No attempt was
made to distinguish cell types in the GCL. Measurements
were obtained 1 mm dorsal and ventral to the optic disc.
For each eye, results obtained from four separate sec-
tions were averaged, and the mean of five eyes was
recorded as the representative value for each group.
Immunofluorescence Studies
Comparative digital images from different samples were
obtained using identical exposure time, brightness, and
contrast settings.
Neuronal Density and GFAP Area in the SC
Digital images with a final magnification of 40 (1000
m2 area) were obtained from the superficial layers (the
stratum zonale and the stratum griseum superficiale) of
the SC from five animals per group. For nuclei density
analysis and GFAP area determination (percentage of
area occupied by astrocyte processes), images were
converted to 8-bit grayscale, and in each case, a manual
threshold value was determined to binarize the images.
For each section, results obtained from two images (in
the medial and lateral areas of the SC) were averaged,
and the mean of three sections from the rostral, medial,
and caudal regions was recorded as the representative
value for each animal.
CTB Studies
CTB staining was quantified as previously described,23with some modifications. Coronal sections (every other
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SC reconstruction using Matlab (The MathWorks Inc.,
Natick, MA). For each section, the retinorecipient SC was
outlined using DAPI counterstaining, and the total retino-
topic area was calculated. Digital images were converted
to 8-bit grayscale, and the optic density of CTB staining
was calculated. The total length was measured and di-
vided into bins (4 m), from the medial to lateral region.
The CTB density was obtained by dividing the total pixel
area by CTB pixels. Finally, a colorimetric thermal rep-
resentation was applied (from 0% blue to 100% red).
The number of sections and the thickness (2) were
used for a final reconstruction of the retinal projection to
the SC.
Statistical Analysis
Statistical analysis of results was performed using two-
way analysis of variance, followed by Dunnett’s test or
Student’s t-test.
Table 1. Body Weight and Blood Glucose Concentration Assess
Time after vehicle or
STZ injection
Body weight (g
Control rats
3 days 326.8  10.0
3 weeks 409.0  12.7
6 weeks 443.6  7.6
15 weeks 485.9  15.8
Data are given as mean  SEM (n  10 animals per group). Significan
after STZ injection.
*P  0.01 versus aged-matched control animals, by Dunnett’s test.
Figure 1. Retinal terminal field in the SC of control rats and of diabetic rats at
patterns in the superficial layers of the SC of control animals and diabetic rats
of a retinotopic SC map reconstruction are also shown. Three weeks after dia
for 6 weeks, a clear reduction in the density of retinal terminals and zones of no CTB s
induction, a similar reduction in the CTB staining pattern density was observed. ShoResults
Table 1 summarizes the mean weight and blood glucose
levels after injection of vehicle or STZ. At 3, 6, and 15
weeks postinjection, significant weight loss and in-
creased blood glucose levels were observed in STZ-
treated rats compared with vehicle-injected rats.
The active anterograde transport of RGC projections to
the SC at different time points after diabetes induction
was analyzed using CTB. In control animals, CTB labeled
the entire retinotopic projection to the stratum zonale and
the stratum griseum superficiale, the most superficial lay-
ers of the SC (Figure 1). No alterations were found in CTB
labeling 3 weeks after diabetes induction, whereas 6
weeks after diabetes onset, a clear reduction in CTB
staining was observed in the central and lateral regions of
the SC, extending in the rostral to caudal direction. In the
lateral region, areas with virtually no CTB staining were
also observed (Figure 1). A similar staining profile was
observed after 15 weeks of diabetes (Figure 1).
ifferent Time Points
Blood glucose concentration (mg/dL)
ic rats Control rats Diabetic rats
9.8 115.1  5.1 467.7  18.8*
7.7* 104.9  9.7 519.6  16.8*
14.1* 108.2  8.2 537.6  13.7*
18.5* 118.0  10.8 565.6  15.4*
ses in body weight and increases in blood glucose levels were observed
t time points after STZ injection. Photomicrographs showing the CTB staining
representative sections (rostral, medial, and caudal) are shown. Dorsal views
duction, no signs of alterations were observed. In animals that were diabeticed at D
)
Diabet
334.8 
311.3 
312.5 
305.7 
t decreadifferen
. Three
betes intaining were found, especially in the lateral area. Fifteen weeks after diabetes
wn are images representative of five animals per group. Scale bar  1 mm.
, inner
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number of cells in the GCL significantly decreased after
15 (but not 3 or 6) weeks of diabetes induction (Figure
2F). At this time point, a significant increase in the num-
ber of TUNEL cells in the GCL was observed in diabetic
rats (Figure 2G). At all the assessed time points, no other
morphologic alterations or differences in total retina and
retinal layer thicknesses were observed (see Supplemen-
tal Table S1 at http://ajp.amjpathol.org).
Histologic analysis of the SC at different time points
after diabetes induction revealed no substantial altera-
tions in its cytoarchitecture (Figure 3). No significant dif-
ferences in the number of neurons were found in the SC
of diabetic animals (Figure 3B), apoptotic cells were ab-
sent (data not shown), and no signs of reactive astrocytes
were evident (Figure 3, C–G).
The ON was morphometrically evaluated at different
regions (Figure 4). Six weeks after diabetes induction, no
changes were observed in transverse sections obtained
from the intraorbital myelinated ON portions (Figure 4, A
and F). In contrast, clear alterations were evident at the
distal region (ie, intracranial ON, near the optic chiasm)
(Figure 4, B and G). Light microscopic morphometry of
semithin sections of the distal ON revealed significant
decreases in the total number of axons (Figure 4D) and
the mean axon area (Figure 4E) compared with age-
matched controls. The myelinated axon area frequency
histograms revealed a clear shift to a smaller-sized area
(Figure 4, C and H), with a significant decrease in large
fiber number (Figure 4I). No significant morphometric
differences were observed in the proximal myelinated
portion (data not shown). For all the ON regions analyzed,
no differences in the total area were found (data not
shown). The proximal region (ie, the intraorbital ON, close
Figure 2. GCL cell loss in diabetic animals. A–D: Representative photomic
animals 3, 6, and 15 weeks after diabetes induction. E: TUNEL cells in th
counterstained with DAPI. F: Cell count in the GCL evaluated by H&E stain
that were diabetic for 15 (but not 3 and 6) weeks than in controls. Scale bar
versus age-matched controls, by Dunnett’s test. INL, inner nuclear layer; IPL
retinal ganglion cell layer.to the ON head), named the glial lamina, contains unmy-elinated axons surrounded by a meshwork of astrocytes
(GFAP immunoreactive). Beyond this area, axons be-
come myelinated toward the chiasm (Figure 5, A–D).
Immunostaining of GFAP in transverse ON sections was
examined at different portions (Figure 5). No signs of glial
reactivity were observed in the intraorbital ON portion (at
the glial lamina and the myelinated region) in diabetic
animals (Figure 5, E, F, I, and J). In the distal portion,
diabetic ON astrocytes showed a reactive morphology
with an increased number of processes (Figure 5K). Mea-
surement of the GFAP area revealed a significant in-
crease in GFAP levels compared with controls (Figure 5,
G and H). In all the sections analyzed, the number of
nuclei remained unchanged (Figure 5L).
Figure 6 shows MBP immunostaining in horizontal
sections obtained at the optic chiasm level. Slight dis-
organization of myelin, with some demyelinated zones,
was observed in the diabetic distal ON and optic tract
(Figure 6D). Double-labeling analysis revealed that
zones of demyelination were occupied by GFAP cells
(Figure 6F). To analyze oligodendrocyte (OL) lineage,
immature OL (O1 cells) and OL progenitors
(PDGFR- cells) were examined. In the diabetic ON,
a marked increase in O1 immunoreactivity was found
(Figure 7). O1 cells showed hypertrophic somas and
a high number of processes (Figure 7). Similarly, a
marked increase in PDGFR- immunolabeling, with a
high number of hypertrophic cells, was observed in the
distal ON (Figure 7).
At the ultrastructural level, alterations and loss of larger
axons were observed in the distal ON from animals that
were diabetic for 6 weeks. In these fibers, myelin was
highly disorganized, and frequent lamellar membranous
bodies were observed (Figure 8). Measurements of elec-
s showing the histologic appearance of control rat retinas and retinas from
(arrows) from an animal that was diabetic for 15 weeks. Cell nuclei were
he number of TUNEL cells in the GCL was significantly higher in animals
m (D and E). Data are mean  SEM (n  5 animals per group). *P  0.01
plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer; RGL,rograph
e GCL
ing. G: T
s  50 tron micrographs demonstrated a significant decrease in
(F), an
; SZ, str
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diabetic ON. The mean  SEM axon area was 1.28 
0.02 m2 in control rats and 1.20  0.04 m2 in diabetic
rats. In contrast, analysis of the g-ratio (the ratio of the inner
Figure 3. Morphometric analysis of the SC from control rats and from diabeti
of the coronal sections [rostral (R), medial, and caudal (C) portions] used for th
(C) were evaluated in the superficial layers of the SC. No signs of neuron lo
graphs showing GFAP immunostaining in controls (D) and in rats after 3 (E), 6
by Dunnett’s test. Scale bar  50 m (G). SGS, stratum griseum superficiale
Figure 4. Morphometric analysis of the ON from control rats and from diab
at the proximal and distal myelinated portions from a control (A and B) and a
at the distal ON portion from a representative control (C) and a diabetic rat
an age-matched control. In diabetic rats, significant reductions were found i
controls and in animals after 6 weeks of diabetes. A significant decrease in the num
animals. Data are mean  SEM (n  5 animals per group). *P  0.01 versus age-maxonal diameter to the total outer diameter) revealed no
clear differences between groups. The mean  SEM
g-ratio was 0.70  0.04 in control rats and 0.72  0.05
in diabetic rats.
different time points after STZ injection. A: The squares indicate the locations
itative analysis. Neuronal density (B) and area occupied by GFAP astrocytes
al reactivity were observed in diabetic animals. Representative photomicro-
d 15 (G) weeks of diabetes. Data are mean SEM (n 5 animals per group),
atum zonale.
after 6 weeks of diabetes. Light micrographs of semithin transverse sections
rat (F and G). Size frequency histograms showing the axon area distribution
te the shift to smaller-sized axons found in the diabetic rat compared with
xon number (D) and mean axon area (E). I: Axonal diameter distribution inc rats at
e quant
ss or glietic rats
diabetic
(H). No
n total a
ber of middle and large (but not smaller) axons was observed in diabetic
atched controls, by Student’s t-test. Scale bar  25 m (G).
s optica
200 m
Optic Nerve and Diabetes 309
AJP January 2012, Vol. 180, No. 1No differences in microglial cell morphology assessed
by Griffonia simplicifolia I staining in the distal ON were
observed between control and diabetic animals. More-
over, no increase in CD11b or ED1 cells (markers of
reactive microglia) were observed in the diabetic ON
(see Supplemental Figure S1 at http://ajp.amjpathol.org).
Discussion
CTB is a reliable anterograde tracer that binds specifi-
cally to surface receptors of neurons and is actively taken
up and transported by the axons.24,25 CTB has been
extensively used to analyze the communication between
the retina and its synaptic targets. The present results
demonstrate a deficit in CTB anterograde transport from
Figure 5. Astrocyte analysis at different ON portions from control rats and
through the rat ON showing the glial lamina, the transition zone, and the mye
were obtained along the ON. The pointed lines indicate the arterial blood su
GFAP (red) and MBP (green) immunostaining patterns. The glial lamina (a tr
absence of MBP immunoreactivity. In the myelinated regions, most nerve fib
immunostaining of transverse sections at the proximal (glial lamina and myel
are shown. In the distal portion, the area occupied by astrocytes was signific
remained unchanged (L). Nuclei were counterstained with DAPI [measured a
versus age-matched controls, by Student’s t-test. Scale bars: 100 m (B–D);the retina to the SC, its primary projection site, at an earlystage of diabetes (ie, 6 weeks after injection of STZ). At
this time point, morphologic studies indicated significant
alterations in the distal portion of the ON but no substan-
tial alterations in the retina or SC. After 15 weeks of
diabetes, a significant decrease in cell number and an
increase in TUNEL cell number in the GCL were ob-
served, but no changes in the SC were evident.
The anterograde axonal transport system is responsi-
ble for transporting proteins associated with axonal struc-
ture and synaptic transmitter function to the axon and its
terminals. In the opposite direction is the retrograde ax-
onal transport system, which carries neurotrophic factors
that influence steady-state activities in the cell body. It
was previously reported as a progressive deficit in the
retrograde axonal transport, mainly mediated by large
s after 6 weeks of diabetes. A: Schematic representation of a sagittal section
egion. The horizontal lines (C and D) indicate the location where the sections
the retina and the ON. B–D: Representative photomicrographs showing the
section is shown in C) was characterized by intense GFAP labeling and the
fully myelinated (a transverse section is shown in D). Representative GFAP
vel) and distal ON portions from a normal rat (E–G) and a diabetic rat (I–K)
er in diabetic rats than in controls (H), and the number of nuclei per section
l density (OD)]. Data are mean  SEM (n  5 animals per group). *P  0.01
(K).from rat
linated r
pply of
ansverse
ers were
inated le
ant largaxons, that is evident 1 month after STZ injection and
). In dia
up. Sca
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sults support that early diabetes provokes a “misconnec-
tion” between the retina and the SC, which precedes
RGC death.
Figure 6. Myelin alterations in the diabetic visual pathway. Representative
sections) from control rats (A–C) and from rats after 6 weeks of diabetes (D–F
and glial reactivity. Shown are images representative of five animals per gro
Figure 7. OL linage evaluation. Immature OL (O1 cells) and OL precursor (
(OD) per section. In the distal ON from animals that were diabetic for 6 wee
presence of disorganized and hypertrophic cells. Data are mean  SEM (n  5 anim
Scale bar  50 m.To identify the locus for the transport disruption along
the visual pathway, representative intraorbital (unmyeli-
nated and myelinated) and intracranial ON sections were
analyzed. In diabetic rats, the distal (intracranial) portion
icrographs of MBP and GFAP immunostaining of the distal ON (horizontal
betic rats, myelin disorganization was observed. Note zones of demyelization
le bar  50 m (F).
 cells) were evaluated by immunostaining and measured as optical density
ficantly increased O1 and PDGFR- immunostaining was observed, with thephotomPDGFR-
ks, signials per group); *P  0.01 versus age-matched controls, by Student=s t-test.
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AJP January 2012, Vol. 180, No. 1of the ON degenerated at a time point in which the prox-
imal portions remained unchanged. In animals that had
been diabetic for 6 weeks, a large increase in astrocyte
reactivity (as shown by GFAP immunoreactivity) occurred
in the distal (but not the intraorbital) portion of the ON,
which coincided with significant axon loss, making larger
axons significantly more vulnerable than smaller axons.
In agreement, Zhang et al26 described a higher suscep-
tibility of ON large axons in STZ-treated rats. Furthermore,
a preferential loss of ON large axons was demonstrated
in experimental models of glaucoma.27,28 Increases in
astrocyte reactivity have been observed in many neuro-
logic disorders and acute nervous system injuries and
involve increases in gene expression and redistribution of
intermediate filaments, and occasionally increases in
proliferation (reviewed by Escartin and Bonvento29). Al-
though microglial cell activation was described in the
diabetic retina at different stages of the disease,30,31 no
changes in the microglia morphologic appearance (as
shown by Griffonia simplicifolia I staining) or signs of mi-
croglial reactivity were observed in the distal portion of
the ON, at least at 6 weeks of diabetes onset.
Structural analyses of peripheral nerves in humans and
animals with diabetes have shown that the main lesions
involve axonal atrophy and axoglial dysfunction.32 Mor-
phologic studies of ON in autopsy materials demon-
strated gliosis, demyelination, focal infarction, and vas-
cular lesions, especially significant in elderly patients with
a long history of diabetes.33 Ino-ue et al34 showed a
reduction in mean axon size and myelinated fiber atrophy
at 3 months of diabetes induction in rats, whereas in the
present study, changes in the axoglial structure of the
distal ON were observed at an earlier stage of the dis-
ease. Notably, these changes were demonstrated by the
appearance of a marked decrease in corneal sensitivity,
possibly associated with peripheral neuropathy in rats
with 5 weeks of diabetes.35
At the ON head, RGC axons pass unmyelinated into
the nerve. MBP is an important constituent of peripheral
and central nervous system myelin sheaths and plays a
major role in myelin membrane formation and struc-
ture.36,37 Thus, MBP is a reliable index of OL differentia-
tion and myelin formation. In that sense, myelin disar-
rangement shown by alterations and disorganization of
MBP immunoreactivity and profound myelin alterations at
the ultrastructural level were observed in the distal por-
tion of the diabetic ON. In myelin abnormalities and de-
myelination in the central nervous system, OL remyelina-tion is expected.38 After demyelination, a remyelination
process occurs through activation of OL progenitor cells
in the lesion. New OLs then are formed, and insulating
function recovers.39 However, the remyelination process
progressively becomes limited. OL progenitor cells in the
lesion, for unknown reasons, gradually lose the ability to
form myelinating OLs.40 In animals with 6 weeks of dia-
betes, progenitor (PDGFR-) and immature (O1) OLs
showed an altered morphologic appearance, with hyper-
trophic somas and multiple processes. The role of these
cells in progression of the disease needs to be further
examined. It is possible that these reactive cells contrib-
ute to a remyelination state but that the axon loss could
provoke a fail to complete the differentiation to mature
OLs, resulting in aberrant cells that accumulate adjacent
to the lesion sites, similar to that seen in chronic models
of white matter injury.41 In an experimental model of glau-
coma, it was described that OL alteration is not only an
early event but also a central mechanism through which
the axons are damaged, leading to the subsequent death
of RGCs.42 Although DR and glaucoma differ in several
aspects (such as causes, risk factors, and retinal cell
types involved, among many others), based on the pres-
ent results, it is tempting to speculate that a similar se-
quence of events described in glaucoma could occur in
experimental diabetes. However, whether changes in
GFAP, O1, and PDGFR- levels are cause or conse-
quence of the decrease in axon number observed in the
diabetic ON cannot be determined, and, in that sense, a
more detailed temporal course of these alterations will be
examined in the near future. The present results suggest
a progression of RGC degeneration in experimental dia-
betes, where axon dysfunction or degeneration pre-
ceded neuronal loss. In fact, neuronal compartments of-
ten crucially depend on one another for survival, and
molecular defects in one compartment can trigger cellu-
lar degeneration in distant parts of the neuron.43 Evi-
dence of axon degeneration occurring separate from and
before somal degeneration has been observed in many
neurodegenerative diseases, such as Alzheimer disease,
Parkinson disease, and glaucoma.23,44–46 However, the
fact that axoglial alterations at the distal portion of the ON
seems to be the first structural alteration in the diabetic
visual pathway does not imply that the initial neuronal
event is axonal. Instead, a putative sublethal impairment
of RGCs could render them unable to support their ax-
ons, resulting in progressive dying back of the axon to-
Figure 8. Ultrastructural alterations in the dia-
betic ON. Transverse sections of the distal ON
from a control rat (A) and from a rat after 6
weeks of diabetes (B) are shown. In diabetic
animals, clear alterations in the myelin sheaths
of larger axons are observed. Note also the pres-
ence of lamellar bodies (arrows). Shown are
images representative of four animals per group.
Scale bar  2 m.ward the cell body.43 Alternatively, RGC death in exper-
312 Fernandez et al
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axon degeneration. On the other hand, there is a possi-
bility that diabetes causes stress to cells that results in
lower efficiency in their mitochondria functioning. Neu-
rons, particularly RGCs (documented by large numbers
of their axons in the globe), are more dependent on their
mitochondria than are dividing cells. If this were the case,
RGC axonal transport (which requires ATP) would be
affected before the occurrence of RGC death signs, and,
in turn, the interaction between ON axons and glia could
be altered. In this scenario, ON glial complications could
be secondary rather than being a primary cause for ON
alterations. Further studies will clarify whether either com-
partment dies secondarily to the other or whether both
are directly affected by diabetes.
Alterations in the distal ON portion may be involved in
the deficit of anterograde transport to the SC and in
decreased propagation of nerve impulse and visual
evoked potentials,16 contributing to visual disorders ob-
served in early diabetes. In fact, abnormal color vision
and contrast sensitivity have been observed before vas-
culopathy,47 indicating the early presence of neuropathy.
In agreement, a growing body of evidence suggests that
neural and glial complications may precede vascular
changes in DR.3,48,49 In summary, these data indicate,
for the first time, that in experimental diabetes, axonal
alterations at the distal portion of the ON precede RGC
loss. Therefore, early vision loss in diabetes could be
abated by interventions that preserve distal axonal func-
tion before loss of the neuronal substrate.
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